7 Blue-Chip Stocks to Buy Before the Bull Market Returns
The bear market is firmly in place so long as the economy worsens. The incoming recession is a necessary headwind. Although the Federal Reserve would like to avoid that outcome, it will try to avoid a slowdown. The Fed is raising interest rates at an astonishing rate to squash inflation. Until inflation subsides, the central bank will continue its stock unfriendly policy. Eventually, the market will shift from a downtrend and recession to flat growth. Companies that cut costs, protected profitability, and invested in the business will rebound. Blue-chip stocks to buy before the bull market returns must have strong quantitative stock scores . In addition, they need to operate a business that investors may easily understand. These blue-chip stocks have strong value, quality, and growth. Chart courtesy of Stock Rover Investors should build a list of stocks that would lead to a diversified portfolio. In the drug manufacturing space, Abbott Laboratories and JJ have strong earnings power. Medtronic, a medical devices firm, is out of favor.
7 Blue-Chip Stocks to Buy Before the Bull Market Returns
The bear market is firmly in place so long as the economy worsens. The incoming recession is a necessary headwind. Although the Federal Reserve would like to avoid that outcome, it will try to avoid a slowdown. The Fed is raising interest rates at an astonishing rate to squash inflation. Until inflation subsides, the central bank will continue its stock unfriendly policy. Eventually, the market will shift from a downtrend and recession to flat growth. Companies that cut costs, protected profitability, and invested in the business will rebound. Blue-chip stocks to buy before the bull market returns must have strong quantitative stock scores . In addition, they need to operate a business that investors may easily understand. These blue-chip stocks have strong value, quality, and growth. Chart courtesy of Stock Rover Investors should build a list of stocks that would lead to a diversified portfolio. In the drug manufacturing space, Abbott Laboratories and JJ have strong earnings power. Medtronic, a medical devices firm, is out of favor.